ILEX ONCOLOGY 907 545 (ILXO) - 500 Beiträge pro Seite
eröffnet am 13.06.00 00:23:59 von
neuester Beitrag 26.06.00 22:36:08 von
neuester Beitrag 26.06.00 22:36:08 von
Beiträge: 24
ID: 156.588
ID: 156.588
Aufrufe heute: 0
Gesamt: 1.796
Gesamt: 1.796
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 10:33 | 2067 | |
| 08.05.24, 11:56 | 1778 | |
| vor 1 Stunde | 1585 | |
| vor 35 Minuten | 1464 | |
| heute 12:25 | 1120 | |
| vor 2 Minuten | 1106 | |
| vor 1 Stunde | 921 | |
| gestern 17:20 | 829 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,2570 | +96,67 | 108 | |||
| 4. | 4. | 156,46 | -2,31 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,3720 | -7,54 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
Tip: ILEX ONCOLOGY
Kurspotential, kurz bis mittelfristig 48 US$.
Kurspotential, kurz bis mittelfristig 48 US$.
09.06.2000
Ilex Oncology 100 Prozent Chance
Telebörse
Die Finanzexperten der Telebörse empfehlen die Ilex-Oncology-Aktie (WKN 907545) zum Kauf.
Ilex Oncology sei das einzige auf die Krebserforschung spezialisierte Auftragsforschungs-Unternehmen. Ilex führe keine kostspielige Grundlagenforschungen durch, sondern entwickele Medikamente in Lizenz weiter. Derzeit würden sich sieben Medikamente in verschiedenen klinischen Testphasen befinden, weitere stehen kurz vor den Testbeginn, so die Experten. Hoffnungsvollstes Medikament sei derzeit Campath, mit dem eine spezielle Blutkrebsform behandelt werden solle.
Falls Campath die Zulassung durch die US-Gesundheitsbehörde FDI erhält, stehe die Aktie vor einer Neubewertung. Denn Experten würden damit rechnen, dass allein dieses Medikament einen weltweiten Umsatz von 150 bis 200 Millionen Dollar erreiche.
Schon jetzt hätte sich Schering die Vermarktungsrechte gesichert.
Ilex Oncology 100 Prozent Chance
Telebörse
Die Finanzexperten der Telebörse empfehlen die Ilex-Oncology-Aktie (WKN 907545) zum Kauf.
Ilex Oncology sei das einzige auf die Krebserforschung spezialisierte Auftragsforschungs-Unternehmen. Ilex führe keine kostspielige Grundlagenforschungen durch, sondern entwickele Medikamente in Lizenz weiter. Derzeit würden sich sieben Medikamente in verschiedenen klinischen Testphasen befinden, weitere stehen kurz vor den Testbeginn, so die Experten. Hoffnungsvollstes Medikament sei derzeit Campath, mit dem eine spezielle Blutkrebsform behandelt werden solle.
Falls Campath die Zulassung durch die US-Gesundheitsbehörde FDI erhält, stehe die Aktie vor einer Neubewertung. Denn Experten würden damit rechnen, dass allein dieses Medikament einen weltweiten Umsatz von 150 bis 200 Millionen Dollar erreiche.
Schon jetzt hätte sich Schering die Vermarktungsrechte gesichert.
Alles über Ilex Oncology und die Testphasen:
www.ilexoncology.com
sehr interessant..
www.ilexoncology.com
sehr interessant..
Insider Buys ILEX ONCOLOGY INC (ILXO)
Friday, June 9, 2000 12:12 AM
Mail this article to a friend
SOURCE: Form 4
ISSUER: ILEX ONCOLOGY INC
SYMBOL: ILXO
FILER: WEAVER GREGORY L
TITLE: Chief Financial Officer
TRANSACTION: Purchase 1,000 05/10/00 $25.50-$27.00
OWNERSHIP: 1,000
The Form 4 is filed with the Securities and Exchange Commission by any
insider buying or selling their company`s shares. This form must be
filed by the 10th of the month following the month in which the
transaction was executed.
Insider data provided by: Washington Service 202/778-1380 or www.washserv.com
Friday, June 9, 2000 12:12 AM
Mail this article to a friend
SOURCE: Form 4
ISSUER: ILEX ONCOLOGY INC
SYMBOL: ILXO
FILER: WEAVER GREGORY L
TITLE: Chief Financial Officer
TRANSACTION: Purchase 1,000 05/10/00 $25.50-$27.00
OWNERSHIP: 1,000
The Form 4 is filed with the Securities and Exchange Commission by any
insider buying or selling their company`s shares. This form must be
filed by the 10th of the month following the month in which the
transaction was executed.
Insider data provided by: Washington Service 202/778-1380 or www.washserv.com
ILEX Oncology Analyst Coverage
CIBC World Markets
Matt Geller
(212) 667-7000 Leerink, Swann & Company
Robert Uhl
(617) 918-4801
Prudential Vector Healthcare
Robert Toth
(415) 274-4460 Kercheville & Company
Jeff Dabbs
(210) 694-5000
US Bancorp Piper Jaffray
Peter Ginsberg
(612) 303-6456 Stephens, Inc.
Jason Zhang
(501) 377-2583
SG Cowen Securities
Ian Sanderson
(617) 946-3700
Sun Trust Equitable
Brian Rye
(615) 780-9330
Small Caps Online
Jeff Davis
(212) 554-4158
FOR IMMEDIATE RELEASE
ILEX ONCOLOGY ANNOUNCES FIRST QUARTER RESULTS
-- Strong Revenue Growth Fueled by Solid CRO Business Performance --
-- Cash Position Reaches $215 Million Following Equity Offering --
SAN ANTONIO, TEXAS, May 3, 2000 – ILEX Oncology, Inc. (Nasdaq: ILXO) today reported that total revenues for the first quarter ended March 31, 2000 grew 94% to $6.6 million fueled by a higher-than-expected increase in contract research (CRO) services revenue, while the overall quarterly loss dropped to $0.15 per share from $0.36 in the first quarter last year.
"We are off to a strong start in 2000, with progress on our lead product candidate CAMPATHâ and positive trends in our quarterly results," said President and Chief Executive Officer Richard Love. "In an important strategic move, we improved our overall cash position to $215 million at the end of the first quarter, following a private placement of 3 million newly issued shares. We now have the resources as well as the expertise to continue advancing our product pipeline and exploring opportunities to acquire promising new anti-cancer agents."
Commenting on the status of CAMPATH (alemtuzumab), an investigational humanized monoclonal antibody, Love said, "We met an important milestone with the timely submission and acceptance for review of our marketing application in Europe, where we expect the review process to take up to a year. Here in the U.S., the Food and Drug Administration is continuing its review, consistent with priority review procedures, of the Biologics License Application submitted by Millennium & ILEX Partners, L.P. in December, 1999."
Commenting on the performance of the Company’s CRO business, Michael Dwyer, President and Chief Operating Officer of ILEX Oncology Services, Inc., said, "We are beginning to reap the benefits of last year’s strong business development efforts, which generated $25 million in new contract signings during 1999 and expanded our client base by 32%. Revenues for the first quarter of 2000 came in higher than anticipated at $5.6 million, up 124% over the same period last year and up 40% over the fourth quarter of 1999. At the same time, we have begun to achieve targeted levels of profitability.
"The real strategic value of the CRO business, however, lies in our internal development capability and our ability to help bring promising new cancer drugs to market," Dwyer continued. "As an example, our new multiyear services agreement with British Biotech – under which we are completing the ongoing clinical trials of their drug, marimastat, in North America – also included the acquisition of British Biotech’s Annapolis, Maryland, office. This has given us a strategically important East Coast presence, enabling us to interact more effectively with clients, investigators and regulatory bodies based on the East Coast."
Recent Operating Highlights
Completion of a $135 million private placement of 3,000,000 newly issued shares of the Company’s common stock at $45 a share. Net proceeds to the Company, after fees and expenses, were approximately $127 million.
Acceptance of the Marketing Authorization Application for CAMPATH for review by the European Agency for the Evaluation of Medicinal Products.
A 124% increase in revenues from the Company’s CRO business.
Initiation of a second Phase I trial of the Company’s vitamin D3 analog, ILX23-7553.
Recent Publications by Medical Researchers
Presentation of abstracts from 13 independent preclinical studies of ILEX investigational therapies at the American Association for Cancer Research 91st Annual Meeting in early April. Nine studies evaluated the ability of the Company’s angiogenesis inhibitors to halt tumor growth. Four studies evaluated the potential cancer prevention and treatment roles of the Company’s lead chemoprevention candidate eflornithine, its vitamin D3 analog ILX23-7553 and the anti-neoplastic agent APOMINEä , being developed with Symphar S.A. of Geneva.
Publication of two papers this spring in The Journal of Biological Chemistry reporting on two of the Company’s collagen fragments being studied by an independent investigator in relation to angiogenesis and tumor growth.
First Quarter Financial Results
Total revenue for the quarter increased 94% to $6.6 million, compared with $3.4 million in the first quarter of 1999. This includes $5.6 million in revenue from the Company’s CRO business, up 124% from $2.5 million in the same period a year ago.
Research and development (R&D) spending totaled $5.3 million, up 47% from $3.6 million in the first quarter of 1999 due to planned spending increases in the Company’s product pipeline.
Total net loss for the first quarter of 2000 was $3.4 million, or a loss of $0.15 per share, compared to a net loss of $4.5 million, or a loss of $0.36 per share, in the first quarter of 1999.
As of March 31, 2000, ILEX had approximately $215 million in cash, cash equivalents, restricted investments and investments in marketable securities, which included approximately $127 million in net proceeds from the private placement completed in late March. Interest income for the first quarter of 2000 increased 400% to $1.5 million, compared to $0.3 million in the same period last year.
About ILEX
ILEX Oncology, Inc. is a drug development company focused predominantly on the accelerated development of drugs for the treatment and prevention of cancer. The company does this in two ways: by advancing a diversified portfolio of anti-cancer drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the company’s core relationships with international oncology experts, strategic alliances -- providing unparalleled access to patient recruitment for clinical trials, and simultaneous European and US drug development and approval capabilities.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the early stage of ILEX’s compounds under development; risks in technology and product development; failure to successfully complete clinical trials; failure to receive market clearance from regulatory agencies; dependence on third parties and partners and those risks described in ILEX’s Form S-3 filed March 8, 2000 (Commission file #333-32000), and ILEX’s Annual Report on Form 10-K for the year ended December 31, 1999, and in other filings made by ILEX with the SEC. ILEX disclaims any obligation to update these forward-looking statements.
CIBC World Markets
Matt Geller
(212) 667-7000 Leerink, Swann & Company
Robert Uhl
(617) 918-4801
Prudential Vector Healthcare
Robert Toth
(415) 274-4460 Kercheville & Company
Jeff Dabbs
(210) 694-5000
US Bancorp Piper Jaffray
Peter Ginsberg
(612) 303-6456 Stephens, Inc.
Jason Zhang
(501) 377-2583
SG Cowen Securities
Ian Sanderson
(617) 946-3700
Sun Trust Equitable
Brian Rye
(615) 780-9330
Small Caps Online
Jeff Davis
(212) 554-4158
FOR IMMEDIATE RELEASE
ILEX ONCOLOGY ANNOUNCES FIRST QUARTER RESULTS
-- Strong Revenue Growth Fueled by Solid CRO Business Performance --
-- Cash Position Reaches $215 Million Following Equity Offering --
SAN ANTONIO, TEXAS, May 3, 2000 – ILEX Oncology, Inc. (Nasdaq: ILXO) today reported that total revenues for the first quarter ended March 31, 2000 grew 94% to $6.6 million fueled by a higher-than-expected increase in contract research (CRO) services revenue, while the overall quarterly loss dropped to $0.15 per share from $0.36 in the first quarter last year.
"We are off to a strong start in 2000, with progress on our lead product candidate CAMPATHâ and positive trends in our quarterly results," said President and Chief Executive Officer Richard Love. "In an important strategic move, we improved our overall cash position to $215 million at the end of the first quarter, following a private placement of 3 million newly issued shares. We now have the resources as well as the expertise to continue advancing our product pipeline and exploring opportunities to acquire promising new anti-cancer agents."
Commenting on the status of CAMPATH (alemtuzumab), an investigational humanized monoclonal antibody, Love said, "We met an important milestone with the timely submission and acceptance for review of our marketing application in Europe, where we expect the review process to take up to a year. Here in the U.S., the Food and Drug Administration is continuing its review, consistent with priority review procedures, of the Biologics License Application submitted by Millennium & ILEX Partners, L.P. in December, 1999."
Commenting on the performance of the Company’s CRO business, Michael Dwyer, President and Chief Operating Officer of ILEX Oncology Services, Inc., said, "We are beginning to reap the benefits of last year’s strong business development efforts, which generated $25 million in new contract signings during 1999 and expanded our client base by 32%. Revenues for the first quarter of 2000 came in higher than anticipated at $5.6 million, up 124% over the same period last year and up 40% over the fourth quarter of 1999. At the same time, we have begun to achieve targeted levels of profitability.
"The real strategic value of the CRO business, however, lies in our internal development capability and our ability to help bring promising new cancer drugs to market," Dwyer continued. "As an example, our new multiyear services agreement with British Biotech – under which we are completing the ongoing clinical trials of their drug, marimastat, in North America – also included the acquisition of British Biotech’s Annapolis, Maryland, office. This has given us a strategically important East Coast presence, enabling us to interact more effectively with clients, investigators and regulatory bodies based on the East Coast."
Recent Operating Highlights
Completion of a $135 million private placement of 3,000,000 newly issued shares of the Company’s common stock at $45 a share. Net proceeds to the Company, after fees and expenses, were approximately $127 million.
Acceptance of the Marketing Authorization Application for CAMPATH for review by the European Agency for the Evaluation of Medicinal Products.
A 124% increase in revenues from the Company’s CRO business.
Initiation of a second Phase I trial of the Company’s vitamin D3 analog, ILX23-7553.
Recent Publications by Medical Researchers
Presentation of abstracts from 13 independent preclinical studies of ILEX investigational therapies at the American Association for Cancer Research 91st Annual Meeting in early April. Nine studies evaluated the ability of the Company’s angiogenesis inhibitors to halt tumor growth. Four studies evaluated the potential cancer prevention and treatment roles of the Company’s lead chemoprevention candidate eflornithine, its vitamin D3 analog ILX23-7553 and the anti-neoplastic agent APOMINEä , being developed with Symphar S.A. of Geneva.
Publication of two papers this spring in The Journal of Biological Chemistry reporting on two of the Company’s collagen fragments being studied by an independent investigator in relation to angiogenesis and tumor growth.
First Quarter Financial Results
Total revenue for the quarter increased 94% to $6.6 million, compared with $3.4 million in the first quarter of 1999. This includes $5.6 million in revenue from the Company’s CRO business, up 124% from $2.5 million in the same period a year ago.
Research and development (R&D) spending totaled $5.3 million, up 47% from $3.6 million in the first quarter of 1999 due to planned spending increases in the Company’s product pipeline.
Total net loss for the first quarter of 2000 was $3.4 million, or a loss of $0.15 per share, compared to a net loss of $4.5 million, or a loss of $0.36 per share, in the first quarter of 1999.
As of March 31, 2000, ILEX had approximately $215 million in cash, cash equivalents, restricted investments and investments in marketable securities, which included approximately $127 million in net proceeds from the private placement completed in late March. Interest income for the first quarter of 2000 increased 400% to $1.5 million, compared to $0.3 million in the same period last year.
About ILEX
ILEX Oncology, Inc. is a drug development company focused predominantly on the accelerated development of drugs for the treatment and prevention of cancer. The company does this in two ways: by advancing a diversified portfolio of anti-cancer drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the company’s core relationships with international oncology experts, strategic alliances -- providing unparalleled access to patient recruitment for clinical trials, and simultaneous European and US drug development and approval capabilities.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the early stage of ILEX’s compounds under development; risks in technology and product development; failure to successfully complete clinical trials; failure to receive market clearance from regulatory agencies; dependence on third parties and partners and those risks described in ILEX’s Form S-3 filed March 8, 2000 (Commission file #333-32000), and ILEX’s Annual Report on Form 10-K for the year ended December 31, 1999, and in other filings made by ILEX with the SEC. ILEX disclaims any obligation to update these forward-looking statements.
Trading Spotlight
Hallo ILEXaner,
wie schön dass das Interesse an ILEX so langsam steigt(ich bin seit
Januar des Jahres erstmals drin).
Ich hoffe der Markt schlachtet das Ding nicht aus. Fundamental und
auch Charttechnisch sieht es sehr sehr gut aus und wird im Sommer nur
ein Richtung kennen (softig aber stetig!). Der Herbst wird dann noch
einmal sehr spannend.
Testergebnisse Phase III stehen an(hier im Board nachzulesen). Thread: ILEX fast + 10%, wer hat infos !!!!?????
Ciao
wie schön dass das Interesse an ILEX so langsam steigt(ich bin seit
Januar des Jahres erstmals drin).
Ich hoffe der Markt schlachtet das Ding nicht aus. Fundamental und
auch Charttechnisch sieht es sehr sehr gut aus und wird im Sommer nur
ein Richtung kennen (softig aber stetig!). Der Herbst wird dann noch
einmal sehr spannend.
Testergebnisse Phase III stehen an(hier im Board nachzulesen). Thread: ILEX fast + 10%, wer hat infos !!!!?????
Ciao
Ilex Oncology Reiterated `Strong Buy` at Prudential Vector
By Donna Mcdonald
Princeton, New Jersey, June 20 (Bloomberg Data) -- Ilex Oncology Inc. (ILXO US) was reiterated ``strong buy`` by analyst Robert J. Toth at Prudential Vector Healthcare Group. The 12-month target price is $63.00 per share.
By Donna Mcdonald
Princeton, New Jersey, June 20 (Bloomberg Data) -- Ilex Oncology Inc. (ILXO US) was reiterated ``strong buy`` by analyst Robert J. Toth at Prudential Vector Healthcare Group. The 12-month target price is $63.00 per share.
Geb bitte mal ein genauere Erklärung ab!!!!
Wie ist das eigentlich mit dem SEC-Filing. Leute dürfen innerhalb von 90 Tagen Aktien verkaufen.
Haben die das vorher angemeldet und bekoomen jetzt 90 Tage Frist - bitteum Aufklärung!
Jedenfalls zeigt de gestrige Verkaufsdruck doch , dass anscheinend einge Leute nichts von halten, und zwar Leute, dies wiessen müssten
Wie ist das eigentlich mit dem SEC-Filing. Leute dürfen innerhalb von 90 Tagen Aktien verkaufen.
Haben die das vorher angemeldet und bekoomen jetzt 90 Tage Frist - bitteum Aufklärung!
Jedenfalls zeigt de gestrige Verkaufsdruck doch , dass anscheinend einge Leute nichts von halten, und zwar Leute, dies wiessen müssten
Na denn ein Prosit auf die folgende Meldung. Kann ja Ilex einfach nur zugute kommen.
Thema: Millennium bald mit FDA-Genehmigung von Campath
Datum: 21.06.00 19:25:27 (MEZ) - Mitteleurop. Sommerzeit
From: mail@wallstreet-online.de
Reply-to: info@wallstreet-online.de
Millennium bald mit FDA-Genehmigung von Campath
Das Biotechunternehmen Millenium Pharmaceuticals Inc. (Nasdaq : MLNM) steigt
heute schon im Vorfeld einer möglichen Zulassung von Campath
durch die FDA. Der Analyst Bill Tanner von SG
Cowen hält es für möglich, dass Millennium in den
nächsten Tagen eine Nachricht von der amerikanischen FDA (Food&Drug
Administration) erhalten könnte. Die beantragte Arznei Campath ist ein
monoklonaler Antikörper zur Behandlung von chronischer Lymphozytleukämie.
Millennium wird im
Moment mit einem Gewinn von 1 Prozent bei 137-3/8
US-Dollar gehandelt.
Thema: Millennium bald mit FDA-Genehmigung von Campath
Datum: 21.06.00 19:25:27 (MEZ) - Mitteleurop. Sommerzeit
From: mail@wallstreet-online.de
Reply-to: info@wallstreet-online.de
Millennium bald mit FDA-Genehmigung von Campath
Das Biotechunternehmen Millenium Pharmaceuticals Inc. (Nasdaq : MLNM) steigt
heute schon im Vorfeld einer möglichen Zulassung von Campath
durch die FDA. Der Analyst Bill Tanner von SG
Cowen hält es für möglich, dass Millennium in den
nächsten Tagen eine Nachricht von der amerikanischen FDA (Food&Drug
Administration) erhalten könnte. Die beantragte Arznei Campath ist ein
monoklonaler Antikörper zur Behandlung von chronischer Lymphozytleukämie.
Millennium wird im
Moment mit einem Gewinn von 1 Prozent bei 137-3/8
US-Dollar gehandelt.
heute läuft folgende Meldung über die Ticker:
Millennium bald mit FDA-Genehmigung von Campath
Das Biotechunternehmen Millenium Pharmaceuticals Inc. (Nasdaq : MLNM) steigt
heute schon im Vorfeld einer möglichen Zulassung von Campath
durch die FDA. Der Analyst Bill Tanner von SG
Cowen hält es für möglich, dass Millennium in den
nächsten Tagen eine Nachricht von der amerikanischen FDA (Food&Drug
Administration) erhalten könnte. Die beantragte Arznei Campath ist ein
monoklonaler Antikörper zur Behandlung von chronischer Lymphozytleukämie.
Das ist doch eigentlich der Hit für ILXO oder?
Millennium bald mit FDA-Genehmigung von Campath
Das Biotechunternehmen Millenium Pharmaceuticals Inc. (Nasdaq : MLNM) steigt
heute schon im Vorfeld einer möglichen Zulassung von Campath
durch die FDA. Der Analyst Bill Tanner von SG
Cowen hält es für möglich, dass Millennium in den
nächsten Tagen eine Nachricht von der amerikanischen FDA (Food&Drug
Administration) erhalten könnte. Die beantragte Arznei Campath ist ein
monoklonaler Antikörper zur Behandlung von chronischer Lymphozytleukämie.
Das ist doch eigentlich der Hit für ILXO oder?
hier noch mal ein quellenbericht:
Market Pulse
By Michael Baron, CBS MarketWatch
Last Update: 1:40 PM ET Jun 21, 2000: NewsWatch
Indications
ADR Report
Wednesday, June 21, 2000
--1:40 pm Millennium news expected
Millennium Pharmaceuticals (MLNM: news, msgs) is tacking on 2 9/16 to 138 1/2. Both SG Cowen analyst Bill Tanner and Needham & Co. analyst Carolyn Pratt said that they expected regulatory news regarding Campath to come in the next few days. Campath is Millennium`s monoclonal antibody cancer treatment. Pratt said the outcome of the FDA review would have "no meaningful financial or strategic impact on the company." Nevertheless, the stock is now up 15 percent this week. In comparison, Merrill Lynch`s Biotech Holdrs (BBH: news, msgs) is up 13 percent since Friday.
back to Yahoo | More MarketPulse >>
Michael Baron is an online reporter for CBS MarketWatch.
All times are Eastern.
aus:
http://www2.marketwatch.com/pulse/pulseone.asp?source=blq/yh…
Market Pulse
By Michael Baron, CBS MarketWatch
Last Update: 1:40 PM ET Jun 21, 2000: NewsWatch
Indications
ADR Report
Wednesday, June 21, 2000
--1:40 pm Millennium news expected
Millennium Pharmaceuticals (MLNM: news, msgs) is tacking on 2 9/16 to 138 1/2. Both SG Cowen analyst Bill Tanner and Needham & Co. analyst Carolyn Pratt said that they expected regulatory news regarding Campath to come in the next few days. Campath is Millennium`s monoclonal antibody cancer treatment. Pratt said the outcome of the FDA review would have "no meaningful financial or strategic impact on the company." Nevertheless, the stock is now up 15 percent this week. In comparison, Merrill Lynch`s Biotech Holdrs (BBH: news, msgs) is up 13 percent since Friday.
back to Yahoo | More MarketPulse >>
Michael Baron is an online reporter for CBS MarketWatch.
All times are Eastern.
aus:
http://www2.marketwatch.com/pulse/pulseone.asp?source=blq/yh…
Das verstehe jetzt wer will!!!
Millennium und Ilex sind doch bei der Entwicklung
von Campath 50/50-Partner, aber nur Millennium wird
erwähnt und nur Millennium steigt???(immerhin 8% zu
Handelsschluß).Ganz im Gegenteil, Ilex fällt sogar
ein wenig trotz positiver Stimmung bei den Biotechs.
Dabei haben wir doch immer auf solch eine Meldung
gewartet oder habe ich da etwas misverstanden???
So long
Seinfeld (stirnrunzelnd und kopfschüttelnd)
Millennium und Ilex sind doch bei der Entwicklung
von Campath 50/50-Partner, aber nur Millennium wird
erwähnt und nur Millennium steigt???(immerhin 8% zu
Handelsschluß).Ganz im Gegenteil, Ilex fällt sogar
ein wenig trotz positiver Stimmung bei den Biotechs.
Dabei haben wir doch immer auf solch eine Meldung
gewartet oder habe ich da etwas misverstanden???
So long
Seinfeld (stirnrunzelnd und kopfschüttelnd)
Wieso nutzt MLNM jetzt CAMPATH ?????? Ich dachte es ist ein 100% Produkt von ILEX ?????
Keine Panik um Ilex.
Die schaut sich die Really der anderen Bios erst einmal an, und kommt dann mit riesen Schritten!!!
Die schaut sich die Really der anderen Bios erst einmal an, und kommt dann mit riesen Schritten!!!
also das ist mehr schönrederei von dir!
Fakt ist, nach Ende irgendeiner Lock-up Periode haben die Altaktionäre erstmal massiv Kasse gemacht, gerade als ILXO drauf und dran war, nach oben aus der Seitwärtsrange auszubrechen!
Zudem wg. Campath: Für MLNM ist dies nur ein Teil unter vielen., für ILXO dagegen das wichtigste Produkt überhaupt, nämlich ihr erstes marktreifes Produkt!
Eigentlich müsste der Kurs deswegen massiv anziehen. Wenn er jetzt nicht anspringt, wann dann, die News, auf die alle gewartet haben, sind doch jetzt da!?
Fakt ist, nach Ende irgendeiner Lock-up Periode haben die Altaktionäre erstmal massiv Kasse gemacht, gerade als ILXO drauf und dran war, nach oben aus der Seitwärtsrange auszubrechen!
Zudem wg. Campath: Für MLNM ist dies nur ein Teil unter vielen., für ILXO dagegen das wichtigste Produkt überhaupt, nämlich ihr erstes marktreifes Produkt!
Eigentlich müsste der Kurs deswegen massiv anziehen. Wenn er jetzt nicht anspringt, wann dann, die News, auf die alle gewartet haben, sind doch jetzt da!?
Jetzt zieht der Kurs endlich an!
Aktuell bei 31 Dollar = + 7,4%.
Ob die US-Anleger jetzt gemerkt haben,
daß ILEX ganz besonders stark von einer
Campath-Zulassung profitieren würde???
Gruß
Seinfeld
Aktuell bei 31 Dollar = + 7,4%.
Ob die US-Anleger jetzt gemerkt haben,
daß ILEX ganz besonders stark von einer
Campath-Zulassung profitieren würde???
Gruß
Seinfeld
Quelle: www.tradecentre.de
Depotentwicklung seit Jahresanfang: +72%
Ilex Oncology hat zusammen mit Millennium Pharmaceuticals vor einigen Monaten die Zulassung von Campath (einem Krebs-Präperat zum Einsatz gegen Lymphozytleukämie) bei der FDA beantragt. Die Aktie von Ilex Oncology geriet stark unter Druck nachdem bekannt wurde, dass die FDA das Präperat Campath nicht wie ursprünglich vorgesehen im Juli besprechen will. Der Termin wurde auf unbestimmte Zeit verschoben.
Gestern wurde in Zusammenhang mit Millennium Pharmaceuticals bekanntgegeben, dass gute Neuigkeiten von der FDA kurz bevorstehen:
Wednesday, June 21, 2000
--1:40 pm Millennium news expected
Millennium Pharmaceuticals (MLNM: news, msgs) is tacking on 2 9/16 to 138 1/2. Both SG Cowen analyst Bill Tanner and Needham & Co. analyst Carolyn Pratt said that they expected regulatory news regarding Campath to come in the next few days. Campath is Millennium`s monoclonal antibody cancer treatment. Pratt said the outcome of the FDA review would have "no meaningful financial or strategic impact on the company." Nevertheless, the stock is now up 15 percent this week. In comparison, Merrill Lynch`s Biotech Holdrs (BBH: news, msgs) is up 13 percent since Friday.
Von einer Zulassung würde natürlich insbesondere Ilex Oncology profitieren. Es ist jedoch verwunderlich warum der Kurs von Ilex Oncology nicht schon gestern Mittag in den USA auf die Meldung reagiert hat. Deshalb werde ich einen Stop-Kurs setzen.
Transaktionen:
- Kauf: 480 Ilex Oncology zum aktuellen Kurs von 31 Euro in Frankfurt.
Stop Loss: 29 Euro auf Schlusskurs-Basis
- Außerdem: Stop-Loss von 127 Euro auf Schlusskurs-Basis bei dem Depotwert TV Loonland!
Übrigens besitzt auch Schering einen Vertriebsvertrag für Campath in den USA und Europa. Risikobewussten Anlegern empfiehlt sich folgender spekulativer Call-Optionsschein auf Schering:
Emittent: Commerzbank, Basispreis 55 Euro, WKN: 710114, Omega ca. 5,5.
Es wäre sinnvoll den Call bei Kursen des Basiswertes knapp über 55 Euro zu kaufen, bei einem Unterschreiten dieser Marke die Position aber sofort wieder glattzustellen. Bei einem Ansteigen der Schering-Aktie auf 58 Euro beträgt der voraussichtliche Kursgewinn ca. 30%.
Depotentwicklung seit Jahresanfang: +72%
Ilex Oncology hat zusammen mit Millennium Pharmaceuticals vor einigen Monaten die Zulassung von Campath (einem Krebs-Präperat zum Einsatz gegen Lymphozytleukämie) bei der FDA beantragt. Die Aktie von Ilex Oncology geriet stark unter Druck nachdem bekannt wurde, dass die FDA das Präperat Campath nicht wie ursprünglich vorgesehen im Juli besprechen will. Der Termin wurde auf unbestimmte Zeit verschoben.
Gestern wurde in Zusammenhang mit Millennium Pharmaceuticals bekanntgegeben, dass gute Neuigkeiten von der FDA kurz bevorstehen:
Wednesday, June 21, 2000
--1:40 pm Millennium news expected
Millennium Pharmaceuticals (MLNM: news, msgs) is tacking on 2 9/16 to 138 1/2. Both SG Cowen analyst Bill Tanner and Needham & Co. analyst Carolyn Pratt said that they expected regulatory news regarding Campath to come in the next few days. Campath is Millennium`s monoclonal antibody cancer treatment. Pratt said the outcome of the FDA review would have "no meaningful financial or strategic impact on the company." Nevertheless, the stock is now up 15 percent this week. In comparison, Merrill Lynch`s Biotech Holdrs (BBH: news, msgs) is up 13 percent since Friday.
Von einer Zulassung würde natürlich insbesondere Ilex Oncology profitieren. Es ist jedoch verwunderlich warum der Kurs von Ilex Oncology nicht schon gestern Mittag in den USA auf die Meldung reagiert hat. Deshalb werde ich einen Stop-Kurs setzen.
Transaktionen:
- Kauf: 480 Ilex Oncology zum aktuellen Kurs von 31 Euro in Frankfurt.
Stop Loss: 29 Euro auf Schlusskurs-Basis
- Außerdem: Stop-Loss von 127 Euro auf Schlusskurs-Basis bei dem Depotwert TV Loonland!
Übrigens besitzt auch Schering einen Vertriebsvertrag für Campath in den USA und Europa. Risikobewussten Anlegern empfiehlt sich folgender spekulativer Call-Optionsschein auf Schering:
Emittent: Commerzbank, Basispreis 55 Euro, WKN: 710114, Omega ca. 5,5.
Es wäre sinnvoll den Call bei Kursen des Basiswertes knapp über 55 Euro zu kaufen, bei einem Unterschreiten dieser Marke die Position aber sofort wieder glattzustellen. Bei einem Ansteigen der Schering-Aktie auf 58 Euro beträgt der voraussichtliche Kursgewinn ca. 30%.
Guter Tip mit Tradecentre!!
Wieder eine Info-Quelle mehr.
Leider hat heute die Nasdaq nicht so ganz mitgespielt,
speziell der Biotech-Index ist um 5,5% gefallen und
hat somit auch Ilex noch ins Minus rutschen lassen.
Schade!
So long
Seinfeld
Wieder eine Info-Quelle mehr.
Leider hat heute die Nasdaq nicht so ganz mitgespielt,
speziell der Biotech-Index ist um 5,5% gefallen und
hat somit auch Ilex noch ins Minus rutschen lassen.
Schade!
So long
Seinfeld
Schaut Euch auf dieser Seite die Analysten-Meinungen
http://www.quicken.com/investments/estimates/?symbol=ILXO
http://www.quicken.com/investments/estimates/?symbol=ILXO
NEWS!!!
FDA Completes Initial Review of Millennium & ILEX Partners` BLA Submission for Campath
Monday, June 26, 2000 07:31 AM Mail this article to a friend
Health/Medical Writers
CAMBRIDGE, Mass. and SAN ANTONIO, Texas--(BW HealthWire)--June 26, 2000 -- Millennium & ILEX Partners, L.P., a joint venture of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM, news, msgs) and ILEX(TM)Oncology, Inc. (Nasdaq: ILXO, news, msgs), today announced the receipt of a complete response letter from the Food and Drug Administration (FDA) related to the partnership`s Biologics License Application (BLA) for Campath(R)(alemtuzumab), an investigational humanized monoclonal antibody.
In the complete response letter, the FDA delineated the deficiencies noted after complete review of the licensing application, the resolution of which is necessary to continue the review of the application for consideration for marketing approval. The complete review of the Campath(R) application satisfied FDA`s performance goal for priority review under the Prescription Drug User Fee Act (PDUFA). The partnership intends to respond rapidly to the FDA letter, and the agency is expected to reinitiate its review upon receipt of the partnership`s complete response.
The partnership submitted a BLA for the monoclonal antibody Campath(R) with the FDA in December 1999. The FDA accepted the application for filing in February 2000. Campath(R) received "fast track" designation from the FDA and has been undergoing a six-month priority review under PDUFA. The FDA also granted orphan drug designation to Campath(R).
In Europe, the partnership submitted a Marketing Authorization Application in March 2000, which is being reviewed under the European Agency for the Evaluation of Medicinal Products` centralized procedure, required for biotechnology products.
Millennium, a biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of therapeutic products. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium and its affiliates currently employ more than 1,000 people.
ILEX Oncology, Inc. is a drug development company focused predominantly on the accelerated development of drugs for the treatment and prevention of diseases. The company does this in two ways: by advancing a diversified portfolio of therapeutic drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the company`s core relationships with international oncology experts, strategic alliances providing access to patient recruitment for clinical trials, and simultaneous European and US drug development and approval capabilities.
ILEX: Certain statements contained herein, including the company`s intention to respond rapidly to regulatory requests and the company`s expectation of the reinitiation of regulatory review, are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the company`s failure to respond rapidly to regulatory requests; the failure of regulators to reinitiate review of company regulatory applications; the early stage of ILEX`s compounds under development; risks in technology and product development; failure to successfully complete clinical trials; failure to receive market clearance from regulatory agencies; dependence on third parties and partners and those risks described in ILEX`s Form S-3 filed March 8, 2000 (Commission file #333-32000), and ILEX`s Annual Report on Form 10-K for the year ended December 31, 1999, and in other filings made by ILEX with the SEC. ILEX disclaims any obligation to update these forward-looking statements.
Millennium: This press release contains "forward-looking statements." These statements include descriptions of Millennium`s operational plans, expectations about future earnings and other results of operations, views of future industry or market conditions, and other statement that include words like "may," "expects," believes," and "intends," and that describe opinions about future events. Known and unknown risks may cause Millennium`s actual results and performances to be materially different from those expressed or implied by these statements. Some of these risks are: uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to the ability of Millennium and its affiliates to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and more fully explained under the heading "Risk Factors That May Affect Results" in the annual report on Form 10-K filed by Millennium with the Securities and Exchange Commission on February 25, 2000.
FDA Completes Initial Review of Millennium & ILEX Partners` BLA Submission for Campath
Monday, June 26, 2000 07:31 AM Mail this article to a friend
Health/Medical Writers
CAMBRIDGE, Mass. and SAN ANTONIO, Texas--(BW HealthWire)--June 26, 2000 -- Millennium & ILEX Partners, L.P., a joint venture of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM, news, msgs) and ILEX(TM)Oncology, Inc. (Nasdaq: ILXO, news, msgs), today announced the receipt of a complete response letter from the Food and Drug Administration (FDA) related to the partnership`s Biologics License Application (BLA) for Campath(R)(alemtuzumab), an investigational humanized monoclonal antibody.
In the complete response letter, the FDA delineated the deficiencies noted after complete review of the licensing application, the resolution of which is necessary to continue the review of the application for consideration for marketing approval. The complete review of the Campath(R) application satisfied FDA`s performance goal for priority review under the Prescription Drug User Fee Act (PDUFA). The partnership intends to respond rapidly to the FDA letter, and the agency is expected to reinitiate its review upon receipt of the partnership`s complete response.
The partnership submitted a BLA for the monoclonal antibody Campath(R) with the FDA in December 1999. The FDA accepted the application for filing in February 2000. Campath(R) received "fast track" designation from the FDA and has been undergoing a six-month priority review under PDUFA. The FDA also granted orphan drug designation to Campath(R).
In Europe, the partnership submitted a Marketing Authorization Application in March 2000, which is being reviewed under the European Agency for the Evaluation of Medicinal Products` centralized procedure, required for biotechnology products.
Millennium, a biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of therapeutic products. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium and its affiliates currently employ more than 1,000 people.
ILEX Oncology, Inc. is a drug development company focused predominantly on the accelerated development of drugs for the treatment and prevention of diseases. The company does this in two ways: by advancing a diversified portfolio of therapeutic drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the company`s core relationships with international oncology experts, strategic alliances providing access to patient recruitment for clinical trials, and simultaneous European and US drug development and approval capabilities.
ILEX: Certain statements contained herein, including the company`s intention to respond rapidly to regulatory requests and the company`s expectation of the reinitiation of regulatory review, are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the company`s failure to respond rapidly to regulatory requests; the failure of regulators to reinitiate review of company regulatory applications; the early stage of ILEX`s compounds under development; risks in technology and product development; failure to successfully complete clinical trials; failure to receive market clearance from regulatory agencies; dependence on third parties and partners and those risks described in ILEX`s Form S-3 filed March 8, 2000 (Commission file #333-32000), and ILEX`s Annual Report on Form 10-K for the year ended December 31, 1999, and in other filings made by ILEX with the SEC. ILEX disclaims any obligation to update these forward-looking statements.
Millennium: This press release contains "forward-looking statements." These statements include descriptions of Millennium`s operational plans, expectations about future earnings and other results of operations, views of future industry or market conditions, and other statement that include words like "may," "expects," believes," and "intends," and that describe opinions about future events. Known and unknown risks may cause Millennium`s actual results and performances to be materially different from those expressed or implied by these statements. Some of these risks are: uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to the ability of Millennium and its affiliates to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and more fully explained under the heading "Risk Factors That May Affect Results" in the annual report on Form 10-K filed by Millennium with the Securities and Exchange Commission on February 25, 2000.
Millennium, Ilex Need to Give FDA More Information on Campath
By Brian Reid
Cambridge, Massachusetts, June 26 (Bloomberg) -- Millennium Pharmaceuticals Inc. and Ilex Oncology Inc. said U.S. regulators have asked them for additional information on their leukemia drug Campath, delaying approval of the product.
The Food and Drug Administration issued a ``complete response`` letter that spells out deficiencies the companies need to correct before the FDA will approve the drug.
If the FDA approves Campath, the drug would be the first on the market for both companies. They are asking the FDA to approve Campath for chronic lymphocytic leukemia, which affects about 60,000 Americans.
The drug was originally granted so-called priority status, meaning the FDA planned to act on the drug within six months of Dec. 23, when the application was filed. The agency had the option to approve the drug, reject it or ask for additional information.
San Antonio-based Ilex`s shares rose 1 5/8 to 30 1/8 on Friday, while shares of Millennium, based in Cambridge, Massachusetts, fell 4 15/16 to 119 9/16
By Brian Reid
Cambridge, Massachusetts, June 26 (Bloomberg) -- Millennium Pharmaceuticals Inc. and Ilex Oncology Inc. said U.S. regulators have asked them for additional information on their leukemia drug Campath, delaying approval of the product.
The Food and Drug Administration issued a ``complete response`` letter that spells out deficiencies the companies need to correct before the FDA will approve the drug.
If the FDA approves Campath, the drug would be the first on the market for both companies. They are asking the FDA to approve Campath for chronic lymphocytic leukemia, which affects about 60,000 Americans.
The drug was originally granted so-called priority status, meaning the FDA planned to act on the drug within six months of Dec. 23, when the application was filed. The agency had the option to approve the drug, reject it or ask for additional information.
San Antonio-based Ilex`s shares rose 1 5/8 to 30 1/8 on Friday, while shares of Millennium, based in Cambridge, Massachusetts, fell 4 15/16 to 119 9/16
Heute ist bekannt geworden, daß die für die Zulassung von Medikamenten
zuständige US-Behörde FDA den Antrag über die Zulassung des in
Kooperation zwischen Millennium Pharmaceuticals und Ilex Oncology
entwickelten Wirkstoffs Campath beantwortet habe. Die FDA wünsche vor
der Zulassung des Medikaments zusätzliche Informationen. Dies werde
den Zulassungsprozess kurzfristig verzögern. Campath erhalte jedoch
zuvor von der FDA bereits den Status beschleunigter Überprüfung
sowie den erweiterten Patentschutz.(Quelle: Hornblower Fischer)
Gruß
Seinfeld
zuständige US-Behörde FDA den Antrag über die Zulassung des in
Kooperation zwischen Millennium Pharmaceuticals und Ilex Oncology
entwickelten Wirkstoffs Campath beantwortet habe. Die FDA wünsche vor
der Zulassung des Medikaments zusätzliche Informationen. Dies werde
den Zulassungsprozess kurzfristig verzögern. Campath erhalte jedoch
zuvor von der FDA bereits den Status beschleunigter Überprüfung
sowie den erweiterten Patentschutz.(Quelle: Hornblower Fischer)
Gruß
Seinfeld
Was für ein Kursverlauf heute!
Von minus 12% auf plus 9,5%,
geschlossen auf Höchststand von 33 USD.
Anscheinend wird die Mitteilung der
FDA jetzt doch positiver ausgelegt.
Zudem haben heute zwei Analysten ihre
Kursziele von 48 bzw. 63 USD wiederholt.
So long
Seinfeld
Von minus 12% auf plus 9,5%,
geschlossen auf Höchststand von 33 USD.
Anscheinend wird die Mitteilung der
FDA jetzt doch positiver ausgelegt.
Zudem haben heute zwei Analysten ihre
Kursziele von 48 bzw. 63 USD wiederholt.
So long
Seinfeld
dieser intraday Reverasal ist heute inder Tat sehr überraschend
Würde mal den nächsten Tag abwarten, dann weiß man mehr,
nicht dass hier Leute einfach blind sich eingedeckt haben, in Folge des BioRebounds heute?
Würde mal den nächsten Tag abwarten, dann weiß man mehr,
nicht dass hier Leute einfach blind sich eingedeckt haben, in Folge des BioRebounds heute?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 118 | ||
| 84 | ||
| 82 | ||
| 71 | ||
| 54 | ||
| 36 | ||
| 31 | ||
| 25 | ||
| 22 | ||
| 22 |
| Wertpapier | Beiträge | |
|---|---|---|
| 21 | ||
| 20 | ||
| 18 | ||
| 14 | ||
| 14 | ||
| 14 | ||
| 12 | ||
| 12 | ||
| 12 | ||
| 11 |
